PMID- 26293379
OWN - NLM
STAT- MEDLINE
DCOM- 20160601
LR  - 20151109
IS  - 1744-7607 (Electronic)
IS  - 1742-5255 (Linking)
VI  - 11
IP  - 11
DP  - 2015
TI  - Management of pulmonary toxicity associated with targeted anticancer therapies.
PG  - 1695-707
LID - 10.1517/17425255.2015.1080687 [doi]
AB  - INTRODUCTION: Targeted anticancer therapies act by interfering with defined 
      molecular entities and/or biologic pathways. Because of their more specific 
      mechanism of action, adverse events (AEs) on healthy tissues are intended to be 
      minimal, resulting in a different toxicity profile from that observed with 
      conventional cytotoxic chemotherapy. Pulmonary AEs are rare but potentially 
      life-threatening and it is, therefore, critical to recognize early on and manage 
      appropriately. AREAS COVERED: In this review, we aim to offer an overview of both 
      more frequent and rare pulmonary AEs caused by targeted anticancer therapies and 
      discuss possible treatment algorithms. Anti-vascular endothelial growth factor, 
      anti-human epidermal growth factor receptor and anti-CD20 therapy will be 
      reviewed, as well as immune checkpoint inhibitors, anaplastic lymphoma kinase 
      inhibitors and mammalian target of rapamycin inhibitors. EXPERT OPINION: Novel 
      agents used in the treatment of cancer have specific side-effects, the result of 
      allergic reactions, on-target and off-target effects. Clinical syndromes 
      associated with pulmonary toxicity vary from bronchospasms, hypersensitivity 
      reactions, pneumonitis, acute respiratory distress, lung bleeding, pleural 
      effusion to pneumothorax. Knowledge of risk factors, a high index of suspicion 
      and a complete diagnostic work-up are essential for limiting the risk of these 
      events becoming life threatening. The development of treatment algorithms is 
      extremely helpful in managing these events. It is probable that these toxicities 
      will be even more frequent with the introduction of combination therapies with 
      the obvious challenge of discerning the responsible agent.
FAU - Teuwen, Laure-Anne
AU  - Teuwen LA
AD  - a 1 Sint-Augustinus, Resident in Internal Medicine , Oosterveldlaan 24, 2610 
      Wilrijk-Antwerp, Belgium.
FAU - Van den Mooter, Tom
AU  - Van den Mooter T
AD  - b 2 Sint-Augustinus, Resident in Medical Oncology , Oosterveldlaan 24, 2610 
      Wilrijk-Antwerp, Belgium.
FAU - Dirix, Luc
AU  - Dirix L
AD  - c 3 Sint-Augustinus, Medical Oncology , Oosterveldlaan 24, 2610 Wilrijk-Antwerp, 
      Belgium +32 34 433 737 ; +32 34 430 09 ; luc.dirix@gza.be.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150819
PL  - England
TA  - Expert Opin Drug Metab Toxicol
JT  - Expert opinion on drug metabolism & toxicology
JID - 101228422
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Algorithms
MH  - Antineoplastic Agents/*adverse effects/pharmacology/therapeutic use
MH  - Humans
MH  - Lung Diseases/*chemically induced/physiopathology/therapy
MH  - Molecular Targeted Therapy
MH  - Neoplasms/*drug therapy
MH  - Risk Factors
OTO - NOTNLM
OT  - anaplastic lymphoma kinase-inhibitors
OT  - immune checkpoint inhibitors
OT  - interstitial lung disease
OT  - lung toxicity
OT  - mammalian target of rapamycin
OT  - monoclonal antibodies
OT  - pneumonitis
OT  - pulmonary toxicity
OT  - targeted anticancer therapy
OT  - tyrosine kinase inhibitors
EDAT- 2015/08/22 06:00
MHDA- 2016/06/02 06:00
CRDT- 2015/08/22 06:00
PHST- 2015/08/22 06:00 [entrez]
PHST- 2015/08/22 06:00 [pubmed]
PHST- 2016/06/02 06:00 [medline]
AID - 10.1517/17425255.2015.1080687 [doi]
PST - ppublish
SO  - Expert Opin Drug Metab Toxicol. 2015;11(11):1695-707. doi: 
      10.1517/17425255.2015.1080687. Epub 2015 Aug 19.